Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Effectiveness of ONS-5010 Compared to Lucentis® in Subjects With Neovascular Age-related Macular Degeneration; NORSE EIGHT

NCT06190093 is registered in ClinicalTrials.gov with Outlook Therapeutics, Inc. as lead sponsor.

NCT NCT06190093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06190093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Effectiveness of ONS-5010 Compared to Lucentis® in Subjects With Neovascular Age-related Macular Degeneration; NORSE EIGHT
Lead sponsor
Outlook Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
January 24, 2024
Completion date
December 5, 2024
Enrollment
400 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration, neovascular age-related macular degeneration, wet macular degeneration